Liquid chromatography - Mass spectrometry method for the determination of gliclazide in human plasma and application to a pharmacokinetic study of gliclazide sustained release tablets

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 12, 2008, Pages 653-658

  Wang, Cai Yun ^a   Zhang, Wei ^a   Xiang, Bing Ren ^a   Yu, Li Yan ^a   Ma, Peng Cheng ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Antidiabetics; CAS 21187 98 4; Gliclazide, human plasma, liquid chromatography mass spectrometry, pharmacokinetics

Indexed keywords

GLICLAZIDE; GLIPIZIDE; ORAL ANTIDIABETIC AGENT;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG RELEASE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PLASMA; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION;

EID: 58149267825     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296567     Document Type: Article

References (13)

1. Satyanarayana S, Kilari EK. Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Mol Cell Biochem. 2006;291:101-105.
2. Schernthaner G. Gliclazide modified release: A critical review of pharmacodynamic, metabolic and vasoprotective effects. Metabolism. 2003;52:29-34.
3. Song DK, Ashcroft FM. Glimepiride block of cloned β-cell, cardiac and smooth muscle K. ATP.channels. Br J Pharmacol. 2001;133:193-199.
4. Jennings PE, Belch JJF. Free radical scavenging activity of sulphonylureas:a clinical assessment of the effectiveness of gliclazide. Ter Arkh. 2001;73:27-31.
5. Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications. 2000;14:201-206.
6. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;14:313-320.
7. Ziegler O, Drouin P. Hemobiological properties of gliclazide. J Diabetes Complications.1994;8:235-239.
8. Fava D, Cassone-Faldetta M, Laurenti O, De luca O, Ghiselli A, De Mattia G. Gliclazide improves antioxidant status and nitric oxide mediated vasodilation in type 2 diabetes. DiabetMed. 2002;19:752-757.
9. Foroutan SM, Zarghi A, Shafaati A, Khoddam A. Application of monolithic column in quantification of gliclazide in human plasma by liquid chromatography. J Pharm Biomed Anal. 2006;42:513-516.
10. Sweetman SC. The Complete Drug Reference. 34th ed. London: The Pharmaceutical Press; 2005. p. 332.
11. Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM, et al. Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide & Diamicron) in healthy hu-man volunteers. Biopharm Drug Dispos. 2002;23:192-202.
12. Kuo CY, Wu SM. High-performance liquid chromatography with electrochemical detection for analysis of gliclazide in plasma. J Chromatogr A. 2005;1088:131-135.
13. Maurer HH, Kratzsch C, Kraemer T, Peters FT, Weber AA. Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. J Chromatogr B. 2002;773:63-73.